Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Individualized clinical management of patients at risk for Alzheimer's dementia.

Authors:
Richard S Isaacson Hollie Hristov Nabeel Saif Katherine Hackett Suzanne Hendrix Juan Melendez Joseph Safdieh Matthew Fink Madhav Thambisetty George Sadek Sonia Bellara Paige Lee Cara Berkowitz Aneela Rahman Josefina Meléndez-Cabrero Emily Caesar Randy Cohen Pei-Lin Lu Samuel P Dickson Mu Ji Hwang Olivia Scheyer Monica Mureb Matthew W Schelke Kellyann Niotis Christine E Greer Peter Attia Lisa Mosconi Robert Krikorian

Alzheimers Dement 2019 12 31;15(12):1588-1602. Epub 2019 Oct 31.

Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Introduction: Multidomain intervention for Alzheimer's disease (AD) risk reduction is an emerging therapeutic paradigm.

Methods: Patients were prescribed individually tailored interventions (education/pharmacologic/nonpharmacologic) and rated on compliance. Normal cognition/subjective cognitive decline/preclinical AD was classified as Prevention. Mild cognitive impairment due to AD/mild-AD was classified as Early Treatment. Change from baseline to 18 months on the modified Alzheimer's Prevention Cognitive Composite (primary outcome) was compared against matched historical control cohorts. Cognitive aging composite (CogAging), AD/cardiovascular risk scales, and serum biomarkers were secondary outcomes.

Results: One hundred seventy-four were assigned interventions (age 25-86). Higher-compliance Prevention improved more than both historical cohorts (P = .0012, P < .0001). Lower-compliance Prevention also improved more than both historical cohorts (P = .0088, P < .0055). Higher-compliance Early Treatment improved more than lower compliance (P = .0007). Higher-compliance Early Treatment improved more than historical cohorts (P < .0001, P = .0428). Lower-compliance Early Treatment did not differ (P = .9820, P = .1115). Similar effects occurred for CogAging. AD/cardiovascular risk scales and serum biomarkers improved.

Discussion: Individualized multidomain interventions may improve cognition and reduce AD/cardiovascular risk scores in patients at-risk for AD dementia.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jalz.2019.08.198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925647PMC
December 2019

Publication Analysis

Top Keywords

ad/mild-ad classified
4
impairment ad/mild-ad
4
cognitive impairment
4
secondary outcomesresults
4
biomarkers secondary
4
classified early
4
treatment change
4
serum biomarkers
4
early treatment
4
mild cognitive
4
prevention mild
4
normal cognition/subjective
4
compliance normal
4
seventy-four assigned
4
rated compliance
4
cognition/subjective cognitive
4
outcomesresults seventy-four
4
classified prevention
4
decline/preclinical classified
4
cognitive decline/preclinical
4

Keyword Occurance

Similar Publications

© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap